文献速递泌尿生殖技术与安全MRPET

18F-PSMA-1007 PET/MRI在中危至高危前列腺癌初始分期中的临床价值

Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer.
PubMed 文献 · Br J Radiol · 2024-01-01

纳入46例病理证实的中危和/或高危前列腺癌患者,评估18F-PSMA-1007 PET/MRI(含专用盆腔高分辨率多参数MRI)初始分期的效用。PET/MRI对精囊和直肠侵犯的敏感度、特异度、阳性预测值、阴性预测值和准确率均为100%;对膀胱和神经血管束侵犯敏感度低(40%和0%)但特异度高(94.4%和100%);TNM分期与金标准的一致性优于mpMRI-WBMRI。结论认为18F-PSMA-1007 PET/MRI是 promising 的影像方法,可改善局部肿瘤评估并提供精确TNM分期。

要点

  • PET/MRI对精囊和直肠侵犯的诊断准确率均为100%,mpMRI分别为95.7%。
  • PET/MRI对膀胱和神经血管束侵犯敏感度低(40%和0%),特异度高(94.4%和100%)。
  • PET/MRI的TNM分期与金标准一致性优于mpMRI-WBMRI(T、N、M的k值分别为0.84、0.60、0.68)。

核心结论

  • 18F-PSMA-1007 PET/MRI在中危和高危前列腺癌分期中具有高诊断准确度,可改善局部肿瘤评估并提供精确TNM分期。
  • 作者认为18F-PSMA-1007 PET/MRI在此类患者分期中可能具有高诊断准确度,这对治疗选择至关重要。

研究设计与样本

  • 研究纳入46例病理证实的中危和/或高危前列腺癌患者,均接受18F-PSMA-1007 PET/MRI检查,其中包括专用盆腔高分辨率多参数MRI(mpMRI)。
  • 以金标准(原文未具体说明)评估TNM分期一致性,并与mpMRI-WBMRI比较。

诊断标准与关键数值

  • PET/MRI检测精囊和直肠侵犯的敏感度、特异度、阳性预测值、阴性预测值和准确率均为100%。
  • mpMRI检测精囊侵犯的敏感度87.5%、特异度100%、阳性预测值100%、阴性预测值93.8%、准确率95.7%。
  • mpMRI检测直肠侵犯的敏感度50%、特异度100%、阳性预测值100%、阴性预测值95.5%、准确率95.7%。
  • PET/MRI检测膀胱侵犯的敏感度40%、特异度94.4%;检测神经血管束侵犯的敏感度0%、特异度100%。
  • mpMRI检测膀胱和神经血管束侵犯的敏感度和特异度均为100%。

临床应用与阅片要点

  • 18F-PSMA-1007 PET/MRI对精囊和直肠侵犯的诊断准确率高,对膀胱和神经血管束侵犯敏感度低但特异度高。
  • PET/MRI的TNM分期与金标准一致性优于mpMRI-WBMRI,可能有助于治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the utility of 18F-PSMA-1007 PET/MRI in initial staging of intermediate- to high-risk prostate cancer (HRPCa).

METHODS: A total of 46 patients with pathologically verified intermediate and/or HRPCa who underwent 18F-PSMA-1007 PET/MRI with dedicated pelvic high-resolution multiparametric MRI (mpMRI) were included.

RESULTS: PET/MRI showed 100% sensitivity (SN), specificity (SP), positive predictive value (PPV), negative predictive value (NPV), and accuracy in detecting seminal vesicle (SV) and rectal invasion, versus 87.5%, 100%, 100% 93.8%, 95.7% and 50%, 100%,100%, 95.5%, and 95.7% for mpMRI respectively. However, PET/MRI had poor SN (40% and 0%) but high SP (94.4% and 100%) in detection of UB and neurovascular bundle (NV) invasion compared to 100% SN and SP for mpMRI. PET/MRI demonstrated stronger TNM staging agreement with the gold standard than mpMRI-WBMRI. It demonstrated concordance with T, N, and M stages in 40, 41, and 36 patients (k 0.84, 0.60, and 0.68, respectively) versus 29, 33, and 31 patients (k 0.54, 0.22, and 0.50) with accurate over all staging of 38/46 patients versus 30/46 patients (K 0.52 versus 0.22).

CONCLUSION: 18F-PSMA-1007 PET/MRI is a promising imaging modality with high diagnostic accuracy in staging intermediate- and HRPCa; it improves local tumour evaluation and provides precise TNM staging.

ADVANCES IN KNOWLEDGE: 18F-PSMA-1007 PET/MRI could have high diagnostic accuracy as shown in the current study for staging HRPCa patients that is crucial for treatment selection. We think that our study will contribute to the body of knowledge and improve the literature surrounding the clinical uses of integrated 18F-PSMA-1007 PET/MRI.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Ali I, Rezk M, Hamouda D, et al. Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer. Br J Radiol. 2024. PMID: 38265254. doi:10.1093/bjr/tqae021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。